Related references
Note: Only part of the references are listed.Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida et al.
LANCET (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting autophagy in cancer
Jean M. Mulcahy Levy et al.
NATURE REVIEWS CANCER (2017)
MET is required for the recruitment of anti-tumoural neutrophils
Veronica Finisguerra et al.
NATURE (2015)
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
Geraldine Mitou et al.
ONCOTARGET (2015)
Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
Alessandro Furlan et al.
CANCER RESEARCH (2014)
Interactions between Autophagy Receptors and Ubiquitin-like Proteins Form the Molecular Basis for Selective Autophagy
Vladimir Rogov et al.
MOLECULAR CELL (2014)
Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells
Lei Liu et al.
NATURE CELL BIOLOGY (2012)
Autophagy as a target for anticancer therapy
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Share Paper
